5G48 image
Entry Detail
PDB ID:
5G48
Keywords:
Title:
H.pylori Beta clamp in complex with Diflunisal
Biological Source:
Source Organism:
PDB Version:
Deposition Date:
2016-05-06
Release Date:
2017-06-21
Method Details:
Experimental Method:
Resolution:
2.28 Å
R-Value Free:
0.25
R-Value Work:
0.23
R-Value Observed:
0.23
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:DNA POLYMERASE III SUBUNIT BETA
Chain IDs:A, B
Chain Length:374
Number of Molecules:2
Biological Source:HELICOBACTER PYLORI
Ligand Molecules
Primary Citation
Targeting the beta-clamp in Helicobacter pylori with FDA-approved drugs reveals micromolar inhibition by diflunisal.
FEBS Lett. 591 2311 2322 (2017)
PMID: 28656718 DOI: 10.1002/1873-3468.12734

Abstact

The β-clamp is the processivity-promoting factor for most of the enzymes in prokaryotic DNA replication; hence, it is a crucial drug target. In the present study, we investigated the β-clamp from Helicobacter pylori, aiming to seek potential drug molecules against this gastric-cancer-causing bacterium. An in silico screening of Food and Drug Administration (FDA) approved drugs against the H. pylori β-clamp, followed by its in vitro inhibition using a surface competition approach, yielded the drug diflunisal as a positive initial hit. Diflunisal inhibits the growth of H. pylori in the micromolar range. We determined the structure of diflunisal in complex with the β-clamp to show that the drug binds at subsite I, which is a protein-protein interaction site. Successful identification of FDA-approved molecules against H. pylori may lead to better and faster drug development.

Legend

Protein

Chemical

Disease

Primary Citation of related structures